Powered by
OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder

MIAMI, March 22, 2017 (GLOBE NEWSWIRE) -- OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc. (NASDAQ:OPK) announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for OPKO's oligonucleotide-based AntagoNAT (CUR-1916) for the treatment of Dravet Syndrome.  Currently, there is no approved treatment for Dravet Syndrome in the U.S.  On March 7, 2017, OPKO Health received orphan drug designation

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox